Literature DB >> 25083083

Mast cell deficiency exacerbates inflammatory bowel symptoms in interleukin-10-deficient mice.

Hanying Zhang1, Yansong Xue1, Hui Wang1, Yan Huang1, Min Du1, Qiyuan Yang1, Mei-Jun Zhu1.   

Abstract

AIM: To test the role of mast cells in gut inflammation and colitis using interleukin (IL)-10-deficient mice as an experimental model.
METHODS: Mast cell-deficient (Kit (W-sh/W-sh) ) mice were crossbred with IL-10-deficient mice to obtain double knockout (DKO) mice. The growth, mucosal damage and colitis status of DKO mice were compared with their IL-10-deficient littermates.
RESULTS: DKO mice exhibited exacerbated colitis compared with their IL-10-deficient littermates, as shown by increased pathological score, higher myeloperoxidase content, enhanced Th1 type pro-inflammatory cytokines and inflammatory signaling, elevated oxidative stress, as well as pronounced goblet cell loss. In addition, deficiency in mast cells resulted in enhanced mucosal damage, increased gut permeability, and impaired epithelial tight junctions. Mast cell deficiency was also linked to systemic inflammation, as demonstrated by higher serum levels of tumor necrosis factor α and interferon γ in DKO mice than that in IL-10-deficient mice.
CONCLUSION: Mast cell deficiency in IL-10-deficient mice resulted in systematic and gut inflammation, impaired gut barrier function, and severer Th1-mediated colitis when compared to mice with only IL-10-deficiency. Inflammation and impaired gut epithelial barrier function likely form a vicious cycle to worsen colitis in the DKO mice.

Entities:  

Keywords:  Colitis; Inflammation; Inflammatory bowel disease; Interleukin-10; Mast cells; Mice

Mesh:

Substances:

Year:  2014        PMID: 25083083      PMCID: PMC4112873          DOI: 10.3748/wjg.v20.i27.9106

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

Review 1.  Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.

Authors:  Peter C Konturek; T Brzozowski; S J Konturek
Journal:  J Physiol Pharmacol       Date:  2011-12       Impact factor: 3.011

Review 2.  Intestinal mast cells in gut inflammation and motility disturbances.

Authors:  Benedicte Y De Winter; Rene M van den Wijngaard; Wouter J de Jonge
Journal:  Biochim Biophys Acta       Date:  2011-04-08

3.  Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells.

Authors:  Luca Pellegrinet; Veronica Rodilla; Zhenyi Liu; Shuang Chen; Ute Koch; Lluis Espinosa; Klaus H Kaestner; Raphael Kopan; Julian Lewis; Freddy Radtke
Journal:  Gastroenterology       Date:  2011-01-14       Impact factor: 22.682

4.  Mast cells function as an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin J2.

Authors:  Akane Tanaka; Yoshihiro Nomura; Akira Matsuda; Keitaro Ohmori; Hiroshi Matsuda
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-24       Impact factor: 4.249

5.  Mast cells play a critical role in the systemic inflammatory response and end-organ injury resulting from trauma.

Authors:  Changchun Cai; Zongxian Cao; Patricia A Loughran; Sodam Kim; Sophie Darwiche; Sebastian Korff; Timothy R Billiar
Journal:  J Am Coll Surg       Date:  2011-09-14       Impact factor: 6.113

6.  Interleukin (IL)-23 suppresses IL-10 in inflammatory bowel disease.

Authors:  Zhanju Liu; Bai-Sui Feng; Shao-Bo Yang; Xiao Chen; Jingling Su; Ping-Chang Yang
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

7.  Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.

Authors:  Mireille Alhouayek; Didier M Lambert; Nathalie M Delzenne; Patrice D Cani; Giulio G Muccioli
Journal:  FASEB J       Date:  2011-05-06       Impact factor: 5.191

8.  Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray.

Authors:  Seungha Kang; Stuart E Denman; Mark Morrison; Zhongtang Yu; Joel Dore; Marion Leclerc; Chris S McSweeney
Journal:  Inflamm Bowel Dis       Date:  2010-12       Impact factor: 5.325

9.  Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice.

Authors:  Mehmet M Altintas; Adiba Azad; Behzad Nayer; Gabriel Contreras; Julia Zaias; Christian Faul; Jochen Reiser; Ali Nayer
Journal:  J Lipid Res       Date:  2010-12-09       Impact factor: 5.922

10.  Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress.

Authors:  María Vicario; Mar Guilarte; Carmen Alonso; Pinchang Yang; Cristina Martínez; Laura Ramos; Beatriz Lobo; Ana González; Meritxell Guilà; Marc Pigrau; Esteban Saperas; Fernando Azpiroz; Javier Santos
Journal:  Brain Behav Immun       Date:  2010-06-25       Impact factor: 7.217

View more
  8 in total

1.  Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality.

Authors:  Celalettin Ustun; Todd E DeFor; Fatma K Karadag; Hyun Don Yun; Sunita Nathan; Claudio G Brunstein; Bruce R Blazar; Daniel J Weisdorf; Shernan G Holtan; Khalid Amin
Journal:  Blood Adv       Date:  2020-05-26

Review 2.  Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.

Authors:  Lei Zhang; Jun Song; Xiaohua Hou
Journal:  J Neurogastroenterol Motil       Date:  2016-04-30       Impact factor: 4.924

3.  Mast Cells Exert Anti-Inflammatory Effects in an IL10-/- Model of Spontaneous Colitis.

Authors:  E M Lennon; L B Borst; L L Edwards; A J Moeser
Journal:  Mediators Inflamm       Date:  2018-04-17       Impact factor: 4.711

4.  Mast cells are essential intermediaries in regulating IL-33/ST2 signaling for an immune network favorable to mucosal healing in experimentally inflamed colons.

Authors:  Zhigang He; Jian Song; Jie Hua; Muqing Yang; Yuanyuan Ma; Tianyu Yu; Junlan Feng; Bin Liu; Xiaodong Wang; Yue Li; Jiyu Li
Journal:  Cell Death Dis       Date:  2018-12-05       Impact factor: 8.469

Review 5.  Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.

Authors:  Yifei Wang; Bin Huang; Tao Jin; Dickson Kofi Wiredu Ocansey; Jiajia Jiang; Fei Mao
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

6.  Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.

Authors:  Dae J Kang; Genta Kakiyama; Naga S Betrapally; Jeremy Herzog; Hiroshi Nittono; Phillip B Hylemon; Huiping Zhou; Ian Carroll; Jing Yang; Patrick M Gillevet; Chunhua Jiao; Hajime Takei; William M Pandak; Takashi Iida; Douglas M Heuman; Sili Fan; Oliver Fiehn; Takao Kurosawa; Masoumeh Sikaroodi; R B Sartor; Jasmohan S Bajaj
Journal:  Clin Transl Gastroenterol       Date:  2016-08-25       Impact factor: 4.488

7.  A functional IL1RL1 variant regulates corticosteroid-induced sST2 expression in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía Núñez; Marjorie De la Fuente; Karen Dubois-Camacho; Hugo Sepúlveda; Martín Montecino; Alejandro Torres-Riquelme; Paulina García-González; Jonás Chnaiderman; Anna Vossenkamper; Thomas T MacDonald; Daniela Simian; María-Julieta González; John A Cidlowski; Rodrigo Quera; Marcela A Hermoso
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

8.  Fecal Microbiota Transplantation Is Effective in Relieving Visceral Hypersensitivity in a Postinfectious Model.

Authors:  Tao Bai; Lei Zhang; Huan Wang; Wei Qian; Jun Song; Xiaohua Hou
Journal:  Biomed Res Int       Date:  2018-01-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.